Tag: Sapience Therapeutics

Insights and updates

Sapience Therapeutics Presents Clinical Data on Two Lead Programs, Including ST101 Oral Presentation, at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

[ad_1] -ST101 Phase 2 data demonstrates activation of the tumor immune microenvironment in glioblastoma (GBM)– -ST316 Phase 1 data demonstrates antagonism of β-catenin-driven immune exclusion- TARRYTOWN, N.Y., Nov. 9, 2024 /PRNewswire/ — Sapience Therapeutics, Inc., […]

Continue Reading →